Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 5:10:300.
doi: 10.3389/fonc.2020.00300. eCollection 2020.

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer

Hui Yang  1 , Kunlun Wang  1 , Tao Wang  1 , Mengxi Li  1 , Bingxu Li  1 , Shenglei Li  1 , Ling Yuan  1
Affiliations
Review

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer

Hui Yang et al. Front Oncol. .

Abstract

Esophageal cancer (EC) is one of the most common cancers with poor survival in the world. Nowadays, a generous number of clinical trials are underway on the use of immunotherapy in EC patients, especially the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. However, only a few patients could benefit from single-agent therapy. Others need combination therapies to enhance the response rate and survival. In this review, we focus on PD-1/PD-L1 inhibitors and its combination options in EC patients. We also summarized the potential predictive biomarkers for PD-1/PD-L1 inhibitors treatment.

Keywords: combination therapy; esophageal cancer; predictive biomarkers; programmed death-1; programmed death-ligand 1.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. (2019) 69:7–34. 10.3322/caac.215512 - DOI - PubMed
    1. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. (2013) 19:5598–606. 10.3748/wjg.v19.i34.5598 - DOI - PMC - PubMed
    1. Dong J, Levine DM, Buas MF, Zhang R, Onstad L, Fitzgerald RC, et al. . Interactions between genetic variants and environmental factors affect risk of esophageal adenocarcinoma and barrett's esophagus. Clin Gastroenterol Hepatol. (2018) 16:1598–606. 10.1016/j.cgh.2018.03.007 - DOI - PMC - PubMed
    1. Kim J, Bowlby R, Mungall AJ, Robertson AG, Odze RD, Cherniack AD, et al. . Integrated genomic characterization of oesophageal carcinoma. Nature. (2017) 541:169–75. 10.1038/nature20805 - DOI - PMC - PubMed
    1. Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. (2014) 15:894–904. 10.1016/S1470-2045(14)70024-5 - DOI - PubMed